A Phase 2b Randomized, Double-blind, Placebo-Controlled Study of Evaluate and Efficacy of MEDI8897, a Monoclonal Antibody with an extended Half-life Against Respiratory Syncytial Virus in Healthy Preterm Infants

  • Patel, Janak, (PI)

Project: Other project

StatusFinished
Effective start/end date10/28/1610/27/18

Funding

  • AstraZeneca LP: $24,343.84